Disease Domain | Count |
---|---|
Neoplasms | 6 |
Hemic and Lymphatic Diseases | 4 |
Immune System Diseases | 3 |
Top 5 Drug Type | Count |
---|---|
Bispecific killer cell engager (BiKE) | 3 |
CAR-NK | 1 |
Fusion protein | 1 |
Immune cell therapy | 1 |
Top 5 Target | Count |
---|---|
CD16a x CD30 | 1 |
CD16a x FOLR1 | 1 |
CD16a x EGFR | 1 |
CD123 x CD16a | 1 |
Target- |
Mechanism Immunologic cytotoxicity [+1] |
Active Org. Artiva Biotherapeutics, Inc.Startup [+1] |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CD16a modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CD16a modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date10 Oct 2023 |
Sponsor / Collaborator Affimed GmbH [+1] |
Start Date21 Mar 2023 |
Sponsor / Collaborator |
Start Date19 Nov 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Ubilical cord blood derived NK cell therapy (Affimed) | Hodgkin's Lymphoma More | Phase 2 Clinical |
AFM-24 ( CD16a x EGFR ) | Advanced Malignant Solid Neoplasm More | Phase 2 Clinical |
Acimtamig ( CD16a x CD30 ) | CD-30 positive Peripheral T-Cell Lymphoma More | Phase 2 |
AB-101(Artiva Biotherapeutics) | Recurrent Hodgkin Lymphoma More | Phase 2 |
AFM-28 ( CD123 x CD16a ) | CD123 Positive Acute Myeloid Leukemia More | Phase 1 |